WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.63
Volume 15, Issue 13, 283-291. Review Article ISSN 2277–7105

ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL FORMULATION DEVELOPMENT

Manish Chaturvedi[1]*, Anshika Yadav[2]

*[1,2]Seth Vishambhar Nath Institute of Pharmaceutical Sciences Khazoor Gaon, Barabanki.

Article Received on 26 May 2026,
Article Revised on 16 June 2026,
Article Published on 01 July 2026,

https://doi.org/10.5281/zenodo.21023638

***Corresponding Author**

Manish Chaturvedi

Seth Vishambhar Nath Institute of Pharmaceutical Sciences Khazoor gaon, Barabanki.

How to cite this Article: Manish Chaturvedi[1]* Anshika Yadav[2]*. (2026). Artificial Intelligence In Pharmaceutical Formulation Development. World Journal of Pharmaceutical Research, 15(13), 283–291.

ABSTRACT

Drug performance, safety, and therapeutic outcomes are greatly impacted by pharmaceutical formulation design. Historically, development efforts have focused on guaranteeing product stability, bioavailability, and ease of manufacturing, frequently ignoring individual patient requirements. More recently, there has been a growing emphasis on patient-centered formulation strategies that prioritise treatment adherence, acceptability, and ease of administration; factors like age, physiological differences, genetic variability, disease conditions, swallowing capacity, sensory preferences, and lifestyle. By analysing vast and varied datasets to enable well-informed formulation decisions, artificial intelligence (AI) has emerged as a useful tool for addressing these challenges. Drug release behaviour, processing parameters, and formulation components can all be predicted and optimised to meet the needs of individual patients thanks to technologies like deep learning, machine learning, and intelligent modelling systems. This review highlights the potential of AI-driven patient-focused formulation development to change pharmaceutical design into a more accurate and customised field by examining its concepts, methods, practical applications, benefits, drawbacks, and future prospects Pharmaceutical formulation development is undergoing a revolution because to artificial intelligence (AI), which makes data-driven decision-making, predictive modelling, and process optimisation possible. Trial-and-error experimentation, which is time-consuming, expensive, and resource-intensive, is a major component of traditional formulation development. Artificial intelligence (AI) technologies, including as machine learning (ML), deep learning (DL), artificial neural networks (ANNs), and expert systems, provide creative ways to forecast formulation

performance, optimise excipient selection, enhance manufacturing procedures, and improve product quality. The uses of AI in pharmaceutical formulation development, recent developments, advantages, difficulties, regulatory issues, and future prospects are all covered in this review. AI-driven strategies have shown great promise in cutting down on experimental workload, speeding up the commercialisation of pharmaceutical goods, and shortening development times.

KEYWORDS: Pharmaceutical formulation, drug development, artificial intelligence, machine learning, neural networks, quality by design, and predictive modeling.

INTRODUCTION

Artificial Intelligence (AI) advancements are driving a digital shift in the pharmaceutical business. Artificial Intelligence (AI) refers to computational systems that are able to carry out tasks like learning, reasoning, prediction, and decision-making that have historically required human intelligence.[1] Formulation development in the pharmaceutical sciences include creating dosage forms that guarantee patient compliance, safety, efficacy, and medication stability.[2] To find the best formulation variables, traditional formulation development frequently necessitates a great deal of laboratory testing. Smarter methods are now required due to the growing complexity of contemporary pharmacological compounds. Artificial intelligence (AI) has become a potent tool for managing massive datasets, spotting hidden trends, and accurately forecasting future results.[3]

2. Formulation Development Using Artificial Intelligence Technologies

2.1 Machine learning

Without explicit programming, computers can learn from data and make predictions thanks to machine learning. Pharmaceutical formulation frequently employs the following ML algorithms[4]

- Random forest (RF)
- Support Vector Machine (SVM)
- Trees of Decisions
- K-Nearest Neighbour (KNN)
- Models of Gradient Boosting[5]

2.2 ANNs or artificial neural networks

ANNs are frequently employed to describe intricate nonlinear interactions between formulation variables and product performance because they resemble the organization of the human brain.

2.3 DL or deep learning

Several neural network layers are used in deep learning to analyse big datasets and extract intricate aspects that are helpful for formulation optimisation.[6]

2.4 Expert Systems

Expert systems support formulation decision-making and troubleshooting by combining computational rules with pharmaceutical knowledge.[7]

3. AI Uses in the Development of Pharmaceutical Formulations

3.1 Prediction of Drug-Excipient Compatibility

Prior to experimental testing, AI models can forecast how active pharmaceutical ingredients (APIs) and excipients will interact. This speeds up screening procedures and lowers formulation failures.[8]

3.2 Optimisation of Formulation

Formulation variables like these are optimised via machine learning algorithms:

- concentration of polymers
- Levels of surfactants
- The loading of drugs
- Conditions for processing

With fewer experimental trials, AI assists in finding the best formulas.[9]

3.3 Prediction of the Dissolution and Release Profile

Drug dissolving behaviour and release kinetics from tablets, capsules, and controlled-release systems can be precisely predicted using AI models.

3.4 Prediction of Stability

In order to help assess shelf life, predictive AI systems estimate product stability under a variety of environmental circumstances, such as temperature and humidity.[10]

3.5 QbD or Quality by Design

By detecting critical material attributes (CMAs) and critical process parameters (CPPs) that impact product quality, AI improves Quality by Design methodologies.

3.6 Technology for Process Analysis (PAT)

Real-time monitoring and management of pharmaceutical production processes are made possible by AI-integrated PAT systems, guaranteeing constant product quality.[11]

4. AI in Innovative Medication Delivery Systems

AI is being used more and more in sophisticated medicine delivery systems, such as[12]

4.1 Formulations of Nanoparticles

AI helps forecast release behavior, medication loading efficiency, and nanoparticle size.[13]

4.2 Drug Delivery using Liposomes

For improved treatment efficacy, machine learning models optimize process parameters and lipid composition.[14]

4.3 Pharmaceuticals using 3D printing

Recent research has shown how AI and big language models may help choose appropriate excipients for additive manufacturing applications and create customized 3D-printed dosage forms.[15]

4.4 Customized Healthcare

AI improves treatment outcomes by enabling customized dosage form formulation based on patient-specific variables.

5. AI's Advantages for Developing Pharmaceutical Formulations[16]

- Shortened period for development
- Reduced expenses for research and development
- Increased accuracy of predictions
- Improved product quality
- Decreased burden for experiments
- Quicker commercialization and scale-up
- Enhanced adherence to regulations

According to studies, AI-assisted methods can improve formulation performance prediction while drastically reducing trial-and-error experimentation.

6. Difficulties and Restrictions[17]

AI implementation is fraught with difficulties despite its benefits:

6.1 Access to Data

Reliable AI model development requires consistent, high-quality datasets.

6.2 Interpretability of the Model

Many deep learning models operate as "black boxes," making it challenging to explain how decisions are made.[18]

6.3 Regulatory Issues

Transparent validation and verification of AI-based systems are mandated by regulatory bodies.

6.4 Privacy and Data Security

Proprietary pharmaceutical data protection is still a major concern.[19]

6.5 Applicability

When applied to fresh formulations, AI models trained on small datasets could not work well.

7. Regulatory Aspects

A growing number of regulatory bodies, like the European Medicines Agency and the U.S. Food and Drug Administration, are investigating frameworks for implementing AI in pharmaceutical development.[20]Key prerequisites for regulatory approval continue to be validation, transparency, reproducibility, and risk management.

Benefits of Patient-Centered Artificial Intelligence

1. Tailored Care and Improvement of Therapy.[21]

Patient-centered AI enables the analysis of individual patient data, such as genetics, age, severity of sickness, lifestyle, and comorbidities.[22]By facilitating customized drug selection, dosage optimization, and formulation creation, this lowers trial-and-error prescribing and enhances therapeutic outcomes.

2. Improved Patient Security and Reduced Adverse Reactions

AI systems can predict toxicity issues, drug-drug interactions, and patient-specific adverse reactions using real-world data. This proactive risk assessment enhances pharmaceutical safety by lowering preventable adverse drug events[23]

3. Better Clinical Evaluation

By integrating clinical records, imaging, laboratory data, and patient-reported outcomes, patient-centered AI enhances diagnostic accuracy and treatment planning.

4. Enhanced Patient Involvement and Adhere

AI-powered tools that assist patients in learning about their condition and course of treatment include chatbots, virtual assistants, and mobile health applications. Personalized reminders and feedback improve patient involvement in care decisions and treatment compliance.[24]

5. Efficient Drug Development and Formulation Design

Patient-centered[25]AI in pharmaceutical research enhances quality by design (QbD) and Design of Experiments (DoE) approaches by predicting the optimal excipient combinations, release profiles, and dose forms based on patient requirements.

6. Faster and More Accurate Disease Recognition

Machine learning algorithms analyse complex datasets to find early disease tendencies, especially in chronic and rare diseases, leading to timely diagnosis and treatment.[26]

7. Cost-effective Healthcare Services

By reducing unnecessary testing, hospital readmissions, and ineffective treatments, patient-centered AI reduces healthcare expenditures without sacrificing high-quality care.

8. Real-time monitoring and predictive analytics

Continuous patient health parameter monitoring is made possible by wearable technology and remote monitoring systems driven by artificial intelligence. Predictive analytics enables early identification of treatment failure or disease progression.[27]

9. Promotion of Precision and Value-Based Healthcare

In line with precision medicine and value-based care models, patient-centered AI guarantees that treatment decisions are based on individual benefit rather than population averages.

10. Improved Life Quality and Patient Contentment

AI supports a comprehensive approach to healthcare by offering tailored, efficient, and responsive care that enhances patient pleasure, trust, and overall quality of life.[28]

Future regulatory compliance is anticipated to be aided by AI integration with QbD and PAT frameworks.

Future advancements in pharmaceutical formulation powered by AI could include:

- Self-sufficient formulation labs
- Digital twins for production and formulation
- Continuous production with AI support
- Excipient selection using generative AI
- Adaptive process control in real-time
- Platforms for customized medication[29]

Because AI technologies have the potential to lower costs and speed up medication development, pharmaceutical corporations are investing more and more in them. AI might significantly reduce research times when paired with automated laboratory technologies, according to recent business partnerships.[30]

CONCLUSION

By providing predictive, effective, and data-driven methods, artificial intelligence is revolutionizing the development of pharmaceutical formulations. Advanced drug delivery systems, formulation optimization, stability prediction, and process control have all seen significant success with AI technologies including machine learning, deep learning, and neural networks. Ongoing developments are anticipated to further incorporate AI into pharmaceutical research and manufacturing, despite persistent issues with data quality, interpretability, and regulatory approval. A promising route toward quicker, more effective, and customized pharmaceutical product development is AI-driven formulation development.

REFERENCE

1. Paul, S. M. et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov., 2010; 9: 203–214.
2. Vamathevan, J. et al. Applications of machine learning in drug discovery and development. Nat. Rev. Drug Discov., 2019; 18: 463–477.

3. DiMasi, J. A., Grabowski, H. G. & Hansen, R. W. Innovation in the pharmaceutical industry: new estimates of R&D costs. J. Health Econ., 2016; 47: 20–33.
4. Mullard, A. The drug-maker's guide to the galaxy. Nature, 2017; 549: 445–447.
5. Wang, H. et al. Scientific discovery in the age of artificial intelligence. Nature, 2023; 620: 47–60.
6. Van Dis, E. A., Bollen, J., Zuidema, W., Van Rooij, R. & Bockting, C. L. ChatGPT: five priorities for research. Nature, 2023; 614: 224–226.
7. Gemini Team Google. Gemini: a family of highly capable multimodal models. Preprint at https://arxiv.org/abs/2312.11805 (2023).
8. O'Callaghan, J. How OpenAI's text-to-video tool Sora could change science—and society. Nature, 2024; 627: 475–476.
9. Sadybekov, A. V. & Katritch, V. Computational approaches streamlining drug discovery. Nature, 2023; 616: 673–685.
10. Savage, N. Tapping into the drug discovery potential of AI. Biopharm. Deal, https://doi.org/10.1038/d43747-021-00045-7 (2021).
11. Dealmakers, B. Generative AI platforms drive drug discovery dealmaking. Biopharm. Deal. https://doi.org/10.1038/d43747-024-00084-w (2024).
12. Cohen, A. A. et al. A complex systems approach to aging biology. Nat. Aging., 2023; 2: 580–59.
13. Neftci, E. O. & Averbeck, B. B. Reinforcement learning in artificial and biological systems. Nat. Mach. Intell., 2019; 1: 133–143.
14. Steyaert, S. et al. Multimodal data fusion for cancer biomarker discovery with deep learning. Nat. Mach. Intell., 2023; 5: 351–362.
15. You, Y. et al. Artificial intelligence in cancer target identification and drug discovery. Signal Transduct. Target. Ther., 2022; 7: 156.
16. Pun, F. W., Ozerov, I. V. & Zhavoronkov, A. AI-powered therapeutic target discovery. Trends Pharmacol. Sci., 2023; 44: 561–572.
17. Bagherian, M. et al. Machine learning approaches and databases for prediction of drug–target interaction: a survey paper. Brief. Bioinform., 2021; 22: 247–269.
18. Zhang, Z. et al. Graph neural network approaches for drug–target interactions. Curr. Opin. Struct. Biol., 2022; 73: 102327.
19. Catacutan, D. B., Alexander, J., Arnold, A. & Stokes, J. M. Machine learning in preclinical drug discovery. Nat. Chem. Biol., 2024; 20: 960–973.

20. Mullowney, M. W. et al. Artificial intelligence for natural product drug discovery. Nat. Rev. Drug Discov., 2023; 22: 895–916.
21. Al-Worafi, Y. M. Technology for Drug Safety: Current Status and Future Developments (Springer, 2023).
22. Subbiah, V. The next generation of evidence-based medicine. Nat. Med., 2023; 29: 49–58.
23. Acosta, J. N., Falcone, G. J., Rajpurkar, P. & Topol, E. J. Multimodal biomedical AI. Nat. Med., 2022; 28: 1773–1784.
24. Yang, X., Wang, Y., Byrne, R., Schneider, G. & Yang, S. Concepts of artificial intelligence for computer-assisted drug discovery. Chem. Rev., 2019; 119: 10520–10594.
25. Schneider, P. et al. Rethinking drug design in the artificial intelligence era. Nat. Rev. Drug Discov., 2020; 19: 353–364.
26. Chen, H. et al. Drug target prediction through deep learning functional representation of gene signatures. Nat. Commun., 2024; 15: 1853.
27. Tasaki, S. et al. Inferring protein expression changes from mRNA in Alzheimer's dementia using deep neural networks. Nat. Commun., 2022; 13: 655.
28. Rodriguez, S. et al. Machine learning identifies candidates for drug repurposing in Alzheimer's disease. Nat. Commun., 2021; 12: 1033.
29. Schulte-Sasse, R., Budach, S., Hnisz, D. & Marsico, A. Integration of multi-omics data with graph convolutional networks to identify new cancer genes and their associated molecular mechanisms. Nat. Mach. Intell., 2021; 3: 513–526.
30. Hong, C., Cao, Q., Zhang, Z., Tsui, S. K.-W. & Yip, K. Y. Reusability report: capturing properties of biological objects and their relationships using graph neural networks. Nat. Mach. Intell., 2022; 4: 222–226.